Compare IPI & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPI | AVXL |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 380.0M | 388.7M |
| IPO Year | 2007 | 2013 |
| Metric | IPI | AVXL |
|---|---|---|
| Price | $40.26 | $4.75 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $25.00 | $22.00 |
| AVG Volume (30 Days) | 224.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 105.14 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $298,328,000.00 | N/A |
| Revenue This Year | $0.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $49.65 | ★ N/A |
| Revenue Growth | ★ 17.13 | N/A |
| 52 Week Low | $22.55 | $2.86 |
| 52 Week High | $44.16 | $13.99 |
| Indicator | IPI | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 66.99 | 59.02 |
| Support Level | $32.49 | $3.60 |
| Resistance Level | N/A | $4.88 |
| Average True Range (ATR) | 2.35 | 0.25 |
| MACD | 0.66 | 0.06 |
| Stochastic Oscillator | 64.58 | 66.03 |
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, which is also the location of the firm's production facilities.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.